½ÃÀ庸°í¼­
»óǰÄÚµå
1740254

¼¼°èÀÇ VNA ¹× PACS(ÀǷ῵»óÀúÀåÀü¼Û½Ã½ºÅÛ) ½ÃÀå : Á¦Ç° À¯Çüº°, ¸ð´Þ¸®Æ¼º°, ¿ëµµº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº° - ¿¹Ãø(-2030³â)

Vendor Neutral Archive & PACS Market by Product Type, Modality, Application, End User & Region - Global Forecast to 2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: MarketsandMarkets | ÆäÀÌÁö Á¤º¸: ¿µ¹® 289 Pages | ¹è¼Û¾È³» : Áï½Ã¹è¼Û

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ VNA ¹× PACS(ÀǷ῵»óÀúÀåÀü¼Û½Ã½ºÅÛ) ½ÃÀå ±Ô¸ð´Â 2025³â 51¾ï ´Þ·¯¿¡¼­ 2030³â±îÁö 79¾ï 2,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ¿¹Ãø ±â°£¿¡ CAGR 9.2%ÀÇ ¼ºÀåÀÌ Àü¸ÁµË´Ï´Ù.

ÀÇ·á ¿µ»ó µ¥ÀÌÅÍÀÇ ±ÞÁõ, Àü»çÀû »óÈ£¿î¿ë¼º Àüȯ, ¿µ»ó ¿öÅ©Ç÷οì ÃÖÀûÈ­¸¦ À§ÇÑ º¥´õ Á߸³ÀûÀÎ Áß¾Ó ÁýÁᫎ Ç÷§Æû¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡ µîÀÌ ½ÃÀå ¼ºÀåÀÇ ÁÖ¿ä ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÇ·áÀÇ µðÁöÅÐÈ­¸¦ À§ÇÑ ³ë·Â°ú ÀÇ·á Á¤º¸ ±³È¯À» ÃËÁøÇÏ´Â ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©°¡ ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ±×·¯³ª ³ôÀº ±¸Çö ºñ¿ë°ú µ¥ÀÌÅÍ ¸¶À̱׷¹À̼ǿ¡ µû¸¥ º¹À⼺Àº ƯÈ÷ Áß¼Ò±Ô¸ðÀÇ ÀÇ·á±â°üÀÌ Ã·´Ü VNA/PACS¸¦ µµÀÔÇÏ´Â µ¥ ÀÖ¾î ¿©ÀüÈ÷ Å« À庮À¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù.

Á¶»ç ¹üÀ§
Á¶»ç ´ë»ó ¿¬µµ 2024-2030³â
±âÁØ ¿¬µµ 2024³â
¿¹Ãø ±â°£ 2024-2030³â
´ÜÀ§ 10¾ï ´Þ·¯
ºÎ¹® Á¦Ç° À¯Çü, ¸ð´Þ¸®Æ¼, Àü°³, º¥´õ À¯Çü, ¿ëµµ, ÃÖÁ¾»ç¿ëÀÚ, Áö¿ª
´ë»ó Áö¿ª ºÏ¹Ì, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦Ç° À¯Çüº°·Î´Â ¸ÖƼ»çÀÌÆ® VNA ºÎ¹®ÀÌ ¿¹Ãø ±â°£ µ¿¾È °¡Àå ³ôÀº ¼ºÀå·üÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

ÀÇ·á ¿µ»ó ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡ÀÇ ÁÖ¿ä ¿øÀÎÀº ÀÇ·á ½Ã½ºÅÛÀÌ ´Ù¾çÇÑ Áö¸®Àû À§Ä¡¿¡¼­ ¿µ»ó ¿öÅ©Ç÷ο츦 ÃÖÀûÈ­Çϱâ À§ÇØ »óÈ£ ¿î¿ë¼º°ú ½Ã¼³ °£ µ¥ÀÌÅÍ ÅëÇÕÀ» Áß¿ä½ÃÇÏ°Ô µÇ¾ú±â ¶§¹®ÀÔ´Ï´Ù. º´¿ø°ú ÀÇ·á ½Ã½ºÅÛÀÌ ÅëÇÕ ³×Æ®¿öÅ©·Î ÅëÇյʿ¡ µû¶ó ¿øÈ°ÇÑ µ¥ÀÌÅÍ ¾×¼¼½º¿Í °øµ¿ Áø´Ü ÀÛ¾÷À» ÃËÁøÇϱâ À§ÇØ Á¾ÇÕÀûÀÎ ¿µ»ó ÀúÀå¼Ò¸¦ ±¸ÃàÇÏ´Â °ÍÀÌ ÇʼöÀûÀÔ´Ï´Ù. ¶ÇÇÑ, Äڷγª19 ÆÒµ¥¹ÍÀ¸·Î ÀÎÇØ °­È­µÈ ¿ø°Ý Áø´Ü, ¿ø°Ý Áø·á ¹× °¡»ó Áø·á ÇÁ·¹ÀÓ¿öÅ©·ÎÀÇ ÀüȯÀº ¾ðÁ¦ ¾îµð¼­³ª ÀÇ·á ¿µ»ó¿¡ ¾ÈÀüÇÏ°Ô Á¢±ÙÇÒ ¼ö ÀÖ´Â È®Àå °¡´ÉÇÑ ¸ÖƼ»çÀÌÆ® VNAÀÇ Çʿ伺À» °­Á¶Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ã·´Ü ¼Ö·ç¼ÇÀº µ¥ÀÌÅÍ »çÀϷθ¦ ÇØ¼ÒÇϰí À̹ÌÁö Áߺ¹À» ÃÖ¼ÒÈ­ÇÒ »Ó¸¸ ¾Æ´Ï¶ó, ´Ù¾çÇÑ Áø·á°ú¿Í ½Ã¼³ °£ÀÇ Áø·á Á¶Á¤À» °­È­ÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù.

¹èÆ÷º°·Î º¸¸é, On-Premise ¹èÆ÷ ºÎ¹®ÀÌ 2024³â °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.

ÀÇ·á ±â°üÀº ¸ð´ÏÅ͸µÀ» À¯ÁöÇϰí Àå±âÀûÀÎ ºñ¿ë ¿¹Ãø °¡´É¼ºÀ» È®º¸Çϱâ À§ÇØ ÀÎÇÁ¶ó¸¦ On-Premise¿¡ ±¸ÃàÇÏ´Â °ÍÀ» ¼±È£Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â°üµéÀº º¸¾È°ú ¼º´É ¾ÈÁ¤¼ºÀ» ¿ì¼±½ÃÇϰí ÀÖÀ¸¸ç, ÀÌ´Â ÀÚº» ¿¹»ê Æí¼º °üÇà°úµµ ÀÏÄ¡ÇÕ´Ï´Ù. ½ºÅ丮Áö¸¦ »ç³»¿¡¼­ °ü¸®ÇÔÀ¸·Î½á ¾ö°ÝÇÑ µ¥ÀÌÅÍ °Å¹ö³Í½º Ç¥ÁØÀ» ÁؼöÇÏ´Â µ¿½Ã¿¡ ½Å·ÚÇÒ ¼ö ÀÖ´Â À̹Ì¡ ¼º´ÉÀ» ÀϰüµÇ°Ô Á¦°øÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¾ß¿¡¼­ Áß¿äÇÑ °í·Á »çÇ×Àº ÃѼÒÀ¯ºñ¿ë(TCO)ÀÔ´Ï´Ù. Ŭ¶ó¿ìµå ±â¹Ý ¼Ö·ç¼ÇÀº ÀϹÝÀûÀ¸·Î ¹Îø¼ºÀÌ ³ô°í Ãʱâ ÅõÀÚ ºñ¿ëÀÌ Àû°Ô µå´Â ¹Ý¸é, On-Premise ±¸ÃàÀº ƯÈ÷ ±âÁ¸ IT ÆÀ°ú ÀÏÁ¤ ¼öÁØÀÇ À̹Ì¡ ¼ö°¡ ¿ä±¸µÇ´Â ±â°üÀÇ °æ¿ì Àå±âÀûÀÎ ÅõÀÚ ¼öÀÍ·ü(ROI)ÀÌ ´õ ³ôÀº °æ¿ì°¡ ¸¹½À´Ï´Ù. ¶ÇÇÑ, Çϵå¿þ¾îÀÇ È¿À²¼ºÀÌ Çâ»óµÊ¿¡ µû¶ó ·ÎÄà ¹èÆ÷ÀÇ °æÁ¦¼º°ú ¾ÈÁ¤¼ºÀÌ Çâ»óµÇ°í ÀÖ½À´Ï´Ù.

Áö¿ªº°·Î´Â ¾Æ½Ã¾ÆÅÂÆò¾çÀÌ 2025-2030³â °¡Àå ³ôÀº CAGRÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀåÀº ÀÇ·á ¿µ»ó ÀÎÇÁ¶ó¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡, ÀÇ·á Á¢±Ù¼º È®´ë, ½ÅÈï °æÁ¦±Ç Àü¹ÝÀÇ º´¿ø ½Ã½ºÅÛÀÇ ±Þ¼ÓÇÑ µðÁöÅÐÈ­·Î ÀÎÇØ °¡Àå ³ôÀº CAGRÀ» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. Àεµ, Áß±¹, µ¿³²¾Æ½Ã¾Æ ±¹°¡µé¿¡¼­ ¿µ»ó Áø´Ü ±â´ÉÀÌ °­È­µÇ°í ÀÖÀ¸¸ç, ÀÇ·á ±â°üµéÀº ÀÓ»ó ¿µ»ó ¹× °ü·Ã µ¥ÀÌÅ͸¦ °ü¸®Çϱâ À§ÇØ Áß¾Ó ÁýÁᫎ »óÈ£ ¿î¿ë °¡´ÉÇÑ ¼Ö·ç¼ÇÀ» ã°í ÀÖ½À´Ï´Ù. µ¿½Ã¿¡, ±â¼ú ¹ßÀü°ú Ŭ¶ó¿ìµå ÄÄÇ»ÆÃÀÇ È®»êÀ¸·Î ±â¾÷¿ë À̹Ì¡ ¼Ö·ç¼Ç, ƯÈ÷ VNA¿Í PACS´Â ´Ù¾çÇÑ ±Ô¸ðÀÇ ÀÇ·á±â°ü¿¡¼­ È®À强°ú ºñ¿ë È¿À²¼ºÀÌ Çâ»óµÇ°í ÀÖ½À´Ï´Ù. µðÁöÅÐ Çコ Àü·«ÀÌ ±¹°¡Àû Çʼö »çÇ×À¸·Î ¶°¿À¸£¸é¼­ ¿µ»ó ¿öÅ©Ç÷οì ÃÖÀûÈ­, ¹æ»ç¼± µ¥ÀÌÅÍ¿¡ ´ëÇÑ ¿ø°Ý ¾×¼¼½º ÃËÁø, ½Ã¼³ °£ µ¥ÀÌÅÍ »óÈ£¿î¿ë¼º ÃËÁø¿¡ ´ëÇÑ °ü½ÉÀÌ Á¡Á¡ ´õ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¤Ã¥Àº ¿µ»ó Á¤º¸ÀÇ ÅëÇÕÀûÀÌ°í ¿øÈ°ÇÑ °ü¸®¸¦ Áö¿øÇÏ´Â VNA-PACS Ç÷§ÆûÀÌ Á¦°øÇÏ´Â °íÀ¯ÇÑ ÀÌÁ¡°ú Àß ºÎÇÕÇÕ´Ï´Ù.

¼¼°èÀÇ VNA ¹× PACS ½ÃÀå¿¡ ´ëÇØ Á¶»ç ºÐ¼®ÇßÀ¸¸ç, ÁÖ¿ä ÃËÁø¿äÀΰú ¾ïÁ¦¿äÀÎ, °æÀï ±¸µµ, ÇâÈÄ µ¿Çâ µîÀÇ Á¤º¸¸¦ ÀüÇØµå¸³´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­·Ð

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ÁÖ¿ä Á¶»ç °á°ú

  • VNA ¹× PACS ½ÃÀå °³¿ä
  • ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ VNA ¹× PACS ½ÃÀå : Á¦Ç° À¯Çüº°, ±¹°¡º°
  • VNA ¹× PACS ½ÃÀå : Áö¿ªÀû ¼ºÀå ±âȸ
  • VNA ¹× PACS ½ÃÀå : Áö¿ª ±¸¼º
  • VNA ¹× PACS ½ÃÀå : ¼±Áø±¹ ½ÃÀå°ú ½ÅÈï ±¹°¡ ½ÃÀå

Á¦5Àå ½ÃÀå °³¿ä

  • ¼­·Ð
  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
    • ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ±âȸ
    • °úÁ¦
  • »ê¾÷ µ¿Çâ
    • Ŭ¶ó¿ìµå äÅÃ
    • AI¿Í MLÀÇ ÅëÇÕ
    • ¹ë·ù ±â¹Ý ÄÉ¾î ¸ðµ¨
  • ±â¼ú ºÐ¼®
    • ÁÖ¿ä ±â¼ú
    • º¸¿Ï ±â¼ú
    • ÀÎÁ¢ ±â¼ú
  • °í°´ÀÇ ºñÁî´Ï½º¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â µ¿Çâ/È¥¶õ
  • ¹ë·ùüÀÎ ºÐ¼®
  • »ýÅÂ°è ºÐ¼®
  • ÅõÀÚ ¹× ÀÚ±ÝÁ¶´Þ ½Ã³ª¸®¿À
  • PorterÀÇ Five Forces ºÐ¼®
  • ÁÖ¿ä ÀÌÇØ°ü°èÀÚ¿Í ±¸ÀÔ ±âÁØ
  • ÁÖ¿ä ÄÁÆÛ·±½º ¹× À̺¥Æ®(2025³â-2026³â)
  • °¡°Ý ºÐ¼®
    • VNA ¹× PACS ¼Ö·ç¼Ç Æò±Õ ÆÇ¸Å °¡°Ý : Á¦Ç° À¯Çüº°(2024³â)
    • VNA ¹× PACS ¼Ö·ç¼Ç Æò±Õ ÆÇ¸Å °¡°Ý : Áö¿ªº°(Á¤¼º)
  • ±ÔÁ¦ ºÐ¼®
    • ±ÔÁ¦±â°ü, Á¤ºÎ±â°ü, ±âŸ Á¶Á÷
    • ±ÔÁ¦ ±¸Á¶
  • ƯÇ㠺м®
    • ÀλçÀÌÆ® : °üÇÒ°ú ÁÖ¿ä ½ÅûÀÚ ºÐ¼®
    • ÁÖ¿ä Æ¯Çã ¸®½ºÆ®(2020³â-2024³â)
  • »ç·Ê ¿¬±¸ ºÐ¼®
  • ¹ÌÃæÁ· ¿ä±¸¿Í ÃÖÁ¾»ç¿ëÀÚ ±â´ë
  • ºñÁî´Ï½º ¸ðµ¨
    • ±â¾÷ ¶óÀ̼±½Ì ¸ðµ¨
    • SaaS ¸ðµ¨
    • Á¾·® ºô¸µ ¸ðµ¨
    • ÇÏÀ̺긮µå ¸ðµ¨
  • VNA ¹× PACS ½ÃÀå¿¡ ´ëÇÑ ¹Ì±¹ °ü¼¼ÀÇ ¿µÇâ(2025³â)
    • ¼­·Ð
    • ÁÖ¿ä °ü¼¼À²
    • °¡°Ý ¿µÇ⠺м®
    • ±¹°¡/Áö¿ª¿¡ ´ëÇÑ ¿µÇâ
    • ÃÖÁ¾ ÀÌ¿ë »ê¾÷¿¡ ´ëÇÑ ¿µÇâ
    • °á·Ð

Á¦6Àå VNA ¹× PACS(ÀǷ῵»óÀúÀåÀü¼Û½Ã½ºÅÛ) ½ÃÀå : ¸ð´Þ¸®Æ¼º°

  • ¼­·Ð
  • CT
  • ¸¾¸ð±×·¡ÇÇ
  • ÃÊÀ½ÆÄ
  • MRI
  • X¼±
  • PET

Á¦7Àå VNA ¹× PACS(ÀǷ῵»óÀúÀåÀü¼Û½Ã½ºÅÛ) ½ÃÀå : Àü°³ ¸ðµ¨º°

  • ¼­·Ð
  • On-Premise Àü°³ ¸ðµ¨
  • Ŭ¶ó¿ìµå ±â¹Ý Àü°³ ¸ðµ¨
  • ÇÏÀ̺긮µå Àü°³ ¸ðµ¨

Á¦8Àå VNA ¹× PACS(ÀǷ῵»óÀúÀåÀü¼Û½Ã½ºÅÛ) ½ÃÀå : Á¦Ç° À¯Çüº°

  • ¼­·Ð
  • VNA
    • ºÎ¹® VNA
    • º¹¼ö ºÎ¹® VNA
    • ¸ÖƼ »çÀÌÆ® VNA
  • PACS
    • ºÎ¹® PACS
    • º¹¼ö ºÎ¹® PACS
    • ¸ÖƼ »çÀÌÆ® PACS

Á¦9Àå VNA ¹× PACS(ÀǷ῵»óÀúÀåÀü¼Û½Ã½ºÅÛ) ½ÃÀå : º¥´õ À¯Çüº°

  • ¼­·Ð
  • µ¶¸³°è º¥´õ
  • ½áµåÆÄƼ º¥´õ

Á¦10Àå VNA ¹× PACS(ÀǷ῵»óÀúÀåÀü¼Û½Ã½ºÅÛ) ½ÃÀå : ¿ëµµº°

  • ¼­·Ð
  • ½ÉÀå
  • Á¤Çü¿Ü°ú
  • Á¾¾ç
  • ½Å°æ
  • »êºÎÀΰú
  • ±âŸ ¿ëµµ

Á¦11Àå VNA ¹× PACS(ÀǷ῵»óÀúÀåÀü¼Û½Ã½ºÅÛ) ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°

  • ¼­·Ð
  • º´¿ø ¹× Áø·á¼Ò
  • Áø´Ü¼¾ÅÍ
  • ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC)
  • ±âŸ ÃÖÁ¾»ç¿ëÀÚ

Á¦12Àå VNA ¹× PACS(ÀǷ῵»óÀúÀåÀü¼Û½Ã½ºÅÛ) ½ÃÀå : Áö¿ªº°

  • ¼­·Ð
  • ºÏ¹Ì
    • ºÏ¹ÌÀÇ °Å½Ã°æÁ¦ Àü¸Á
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • À¯·´ÀÇ °Å½Ã°æÁ¦ Àü¸Á
    • µ¶ÀÏ
    • ¿µ±¹
    • ÇÁ¶û½º
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ °Å½Ã°æÁ¦ Àü¸Á
    • ÀϺ»
    • Áß±¹
    • Àεµ
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ¶óƾ¾Æ¸Þ¸®Ä«ÀÇ °Å½Ã°æÁ¦ Àü¸Á
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ °Å½Ã°æÁ¦ Àü¸Á
    • GCC ±¹°¡
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦13Àå °æÀï ±¸µµ

  • ¼­·Ð
  • ÁÖ¿ä ½ÃÀå ÁøÃâ±â¾÷ÀÇ Àü·«/°­Á¡
  • ¸ÅÃ⠺м®(2020³â-2024³â)
  • ½ÃÀå Á¡À¯À² ºÐ¼®(2024³â)
  • ±â¾÷ Æò°¡ ¸ÅÆ®¸¯½º : ÁÖ¿ä ±â¾÷(2024³â)
  • ±â¾÷ Æò°¡ ¸ÅÆ®¸¯½º : ½ºÅ¸Æ®¾÷/Áß¼Ò±â¾÷(2024³â)
  • ±â¾÷ Æò°¡¿Í À繫 ÁöÇ¥
    • À繫 ÁöÇ¥
    • ±â¾÷ Æò°¡
  • ºê·£µå/¼ÒÇÁÆ®¿þ¾î ºñ±³
  • °æÀï ½Ã³ª¸®¿À

Á¦14Àå ±â¾÷ °³¿ä

  • ÁÖ¿ä ±â¾÷
    • AGFA-GEVAERT GROUP
    • FUJIFILM HOLDINGS CORPORATION
    • SECTRA AB
    • GE HEALTHCARE
    • MERATIVE
    • KONINKLIJKE PHILIPS N.V.
    • CANON MEDICAL SYSTEMS CORPORATION
    • INTELERAD. INTELERAD.
    • PAXERAHEALTH
    • NOVARAD CORPORATION
    • HYLAND SOFTWARE, INC.
    • SIEMENS HEALTHINEERS AG
    • BRIDGEHEAD SOFTWARE LTD.
    • CANOPY PARTNERS
    • CRELIOHEALTH INC.
    • ASPYRA, LLC
    • POSTDICOM
    • MEDICASOFT
    • ESAOTE S.P.A.
    • VISUS HEALTH IT GMBH
  • ±âŸ ±â¾÷
    • ADVAHEALTH SOLUTIONS
    • SOFTTEAM SOLUTIONS PVT. LTD.
    • ARO SYSTEMS
    • CENTRAL DATA NETWORKS
    • ONEPACS
    • DEDALUS S.P.A.

Á¦15Àå ºÎ·Ï

LSH

The global VNA & PACS market is projected to reach USD 7.92 billion by 2030 from USD 5.10 billion in 2025, at a CAGR of 9.2% during the forecast period. Market expansion is largely fueled by the surging volume of medical imaging data, the transition towards enterprise-wide interoperability, and the increasing demand for centralized, vendor-neutral platforms designed to optimize imaging workflows. Additionally, initiatives aimed at healthcare digitization and regulatory frameworks promoting health information exchange are further catalyzing market growth. However, the high costs associated with implementation and the complexities related to data migration remain significant barriers to the adoption of advanced VNA and PACS, particularly for small to mid-sized healthcare organizations.

Scope of the Report
Years Considered for the Study2024-2030
Base Year2024
Forecast Period2024-2030
Units ConsideredValue (USD billion)
SegmentsProduct Type, Modality, Deployment, Vendor Type, Application, End User, and Region
Regions coveredNorth America, Europe, Asia Pacific, Latin America, and Middle East & Africa

On the basis of product type, the multi-site VNA segment is expected to witness the highest growth rate during the forecast period.

Based on product type, the VNA & PACS market is segmented into VNA (further subsegmented into department, multi-department, and multi-site VNA) and PACS (further subsegmented into department, multi-department, and multi-site PACS). The multi-site VNA subsegment is expected to witness the fastest CAGR during the forecast period. The escalating demand for medical imaging solutions is primarily driven by the increasing emphasis of healthcare systems on interoperability and cross-institutional data integration to optimize imaging workflows across diverse geographical locations. As hospitals and health systems consolidate into integrated networks, the establishment of a comprehensive imaging repository has become essential for facilitating seamless data access and collaborative diagnostic efforts. Additionally, the transition towards remote diagnostics, teleconsultations, and virtual care frameworks-exacerbated by the COVID-19 pandemic-has underscored the imperative for scalable, multi-site VNAs that enable secure and anytime-anywhere access to medical imaging. These advanced solutions not only help dismantle data silos and minimize image duplication but also enhance care coordination across various departments and facilities.

On the basis of deployment, the on-premises deployment segment held the largest market share in 2024.

On the basis of deployment, the VNA & PACS market has been segmented into on-premises, cloud-based, and hybrid deployment. The on-premises deployment segment held the largest market share in 2024. Healthcare institutions are increasingly favoring on-premises deployment in infrastructure to maintain oversight and achieve long-term cost predictability, particularly those with substantial resources or large-scale operations. These organizations prioritize security and performance stability, which aligns well with capital budgeting practices. By managing storage internally, they ensure compliance with stringent data governance standards while consistently delivering reliable imaging performance. A critical consideration in this area is the total cost of ownership (TCO). Although cloud-based solutions typically offer greater agility and require a lower upfront investment, on-premises deployment often provides superior long-term return on investment (ROI), especially for institutions equipped with established IT teams and fixed imaging volume requirements. Furthermore, advancements in hardware efficiencies are making local deployments increasingly economical and dependable.

On the basis of region, the Asia Pacific is expected to witness the highest CAGR from 2025 to 2030.

On the basis of region, the VNA & PACS market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. Among these, the Asia Pacific market is expected to witness the highest CAGR due to an increased investment in medical imaging infrastructure, expanding healthcare access, and the rapid digitization of hospital systems across emerging economies. Countries such as India, China, and various Southeast Asian nations are enhancing their diagnostic imaging capabilities, leading healthcare organizations to explore centralized and interoperable solutions for the management of clinical images and associated data. Concurrently, technological advancements and the increasing adoption of cloud computing are rendering enterprise imaging solutions-specifically VNA and PACS-more scalable and cost-efficient across institutions of varying sizes. As digital health strategies emerge as national imperatives, there is an intensified focus on optimizing imaging workflows, facilitating remote access to radiological data, and promoting cross-facility data interoperability. These objectives are well-aligned with the inherent advantages offered by VNA and PACS platforms, which support integrated and seamless management of imaging information.

The breakdown of primary participants is as mentioned below:

  • By Company Type - Tier 1: 45%, Tier 2: 30%, and Tier 3: 25%
  • By Designation - C-level: 42%, Director-level: 31%, and Others: 27%
  • By Region - North America: 32%, Europe: 30%, Asia Pacific: 25%, Middle East & Africa: 5%, Latin America: 5%

Key Players

The key players functioning in the VNA & PACS market include Hyland Software, Inc. (US), Agfa-Gevaert Group (Belgium), Intelerad Medical Systems Inc. (Canada), Canon Medical Systems Corporation (Japan), FUJIFILM Holdings Corporation (Japan), GE Healthcare (US), Merative (US), Sectra AB (Sweden), Siemens Healthcare Limited (Germany), BridgeHead Software Ltd. (UK), Canopy Partners. (US), Novarad Corporation (US), POSTDICOM (Netherlands), AdvaHealth Solutions Pte Ltd. (Singapore), CrelioHealth (India), Medicasoft (US), Esaote S.p.A. (Italy), PaxeraHealth (US), VISUS Health IT GmbH (Germany), ASPYRA, LLC (US), Dedalus S.p.A. (Italy), SoftTeam Solutions Pvt. Ltd. (India), ARO Systems (Australia), Central Data Networks (Australia), and ONEPACS (US).

Research Coverage:

The report analyses the VNA & PACS market to estimate the market size and future growth potential of various market segments based on product type, modality, deployment, vendor type, application, end user, and region. The report also provides a competitive analysis of the key players in this market, along with their company profiles, product offerings, recent developments, and key market strategies.

Reasons to Buy the Report

This report provides valuable insights for both established firms and emerging or smaller players, enabling them to accurately assess market dynamics. By leveraging the information presented, organizations can adopt various strategies outlined below to enhance their competitive positioning and increase market share..

This report provides insights on:

  • Analysis of DROCs: Drivers [increasing investments in medical imaging technologies, growing demand for streamlined healthcare data management solutions, Integration of PACS/VNA with electronic medical records (EMRs)], restraints [increasing data security and privacy concerns, high initial investment, lack of standardized protocols and interoperability frameworks], opportunities [government initiatives to increase penetration of AI in medical imaging, Increasing medical imaging procedures and large imaging data silos, rapid uptake of big data in healthcare], and challenges [rising security concerns related to cloud-based image processing and analytics, data security issues] influencing the growth of the VNA & PACS market.
  • Product Development/Innovation: Detailed insights on upcoming technologies, R&D activities, and new product & service launches in the VNA & PACS market
  • Market Development: Comprehensive information on the lucrative emerging markets, product type, modality, deployment, vendor type, application, end user, and region.
  • Market Diversification: Exhaustive information about the product portfolios, growing geographies, recent developments, and investments in the VNA & PACS market
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, and capabilities of the leading players in the VNA & PACS market, such as Agfa-Gevaert Group (Belgium), FUJIFILM Holdings Corporation (Japan), Sectra AB (Sweden), Merative (US), and GE Healthcare (US).

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
  • 1.3 STUDY SCOPE
    • 1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE
    • 1.3.2 INCLUSIONS & EXCLUSIONS
    • 1.3.3 YEARS CONSIDERED
    • 1.3.4 CURRENCY CONSIDERED
  • 1.4 STAKEHOLDERS
  • 1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • 2.1.1 SECONDARY DATA
      • 2.1.1.1 Key secondary sources
      • 2.1.1.2 Key data from secondary sources
    • 2.1.2 PRIMARY DATA
      • 2.1.2.1 Key primary sources
      • 2.1.2.2 Key objectives of primary research
      • 2.1.2.3 Key data from primary sources
      • 2.1.2.4 Key primary insights
  • 2.2 RESEARCH DESIGN
  • 2.3 MARKET SIZE ESTIMATION
    • 2.3.1 SUPPLY-SIDE ANALYSIS (REVENUE SHARE ANALYSIS)
    • 2.3.2 BOTTOM-UP APPROACH
    • 2.3.3 TOP-DOWN APPROACH
    • 2.3.4 TOP-DOWN APPROACH FOR PARENT MARKET ASSESSMENT
    • 2.3.5 COMPANY PRESENTATIONS AND PRIMARY INTERVIEWS
  • 2.4 DATA TRIANGULATION
  • 2.5 STUDY ASSUMPTIONS
  • 2.6 RISK ANALYSIS
  • 2.7 RESEARCH LIMITATIONS
    • 2.7.1 METHODOLOGY-RELATED LIMITATIONS
    • 2.7.2 SCOPE-RELATED LIMITATIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

  • 4.1 OVERVIEW OF VNA & PACS MARKET
  • 4.2 ASIA PACIFIC: VNA & PACS MARKET, BY PRODUCT TYPE AND COUNTRY
  • 4.3 VNA & PACS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
  • 4.4 VNA & PACS MARKET: REGIONAL MIX
  • 4.5 VNA & PACS MARKET: DEVELOPED VS. EMERGING MARKETS

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • 5.2.1 DRIVERS
      • 5.2.1.1 Heightened investments in medical imaging technologies
      • 5.2.1.2 Growing demand for streamlined healthcare data management solutions
      • 5.2.1.3 Integration of PACS/VNA with electronic medical records
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 High initial investment for implementing VNA and PACS solutions
      • 5.2.2.2 Lack of standardized protocols and interoperability frameworks
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Favorable government initiatives for better penetration of AI in medical imaging
      • 5.2.3.2 Increasing medical imaging procedures and large imaging data silos
      • 5.2.3.3 Rapid uptake of big data in healthcare
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Rising security concerns related to cloud-based image processing and analytics
      • 5.2.4.2 Data security issues in healthcare settings
  • 5.3 INDUSTRY TRENDS
    • 5.3.1 CLOUD ADOPTION
    • 5.3.2 AI AND ML INTEGRATION
    • 5.3.3 VALUE-BASED CARE MODELS
  • 5.4 TECHNOLOGY ANALYSIS
    • 5.4.1 KEY TECHNOLOGIES
      • 5.4.1.1 Digital imaging and communications in medicine (DICOM)
      • 5.4.1.2 Enterprise imaging solutions
      • 5.4.1.3 Cloud-based storage and services
    • 5.4.2 COMPLEMENTARY TECHNOLOGIES
      • 5.4.2.1 Image exchange networks
      • 5.4.2.2 Data analytics and business intelligence
    • 5.4.3 ADJACENT TECHNOLOGIES
      • 5.4.3.1 Health information exchange (HIE)
  • 5.5 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
  • 5.6 VALUE CHAIN ANALYSIS
  • 5.7 ECOSYSTEM ANALYSIS
    • 5.7.1 ROLE IN ECOSYSTEM
  • 5.8 INVESTMENT & FUNDING SCENARIO
  • 5.9 PORTER'S FIVE FORCES ANALYSIS
    • 5.9.1 INTENSITY OF COMPETITIVE RIVALRY
    • 5.9.2 BARGAINING POWER OF SUPPLIERS
    • 5.9.3 BARGAINING POWER OF BUYERS
    • 5.9.4 THREAT OF NEW ENTRANTS
    • 5.9.5 THREAT OF SUBSTITUTES
  • 5.10 KEY STAKEHOLDERS & BUYING CRITERIA
    • 5.10.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • 5.10.2 KEY BUYING CRITERIA
  • 5.11 KEY CONFERENCES & EVENTS, 2025-2026
  • 5.12 PRICING ANALYSIS
    • 5.12.1 AVERAGE SELLING PRICE OF VNA & PACS SOLUTIONS, BY PRODUCT TYPE, 2024
    • 5.12.2 AVERAGE SELLING PRICE OF VNA & PACS SOLUTIONS, BY REGION (QUALITATIVE)
  • 5.13 REGULATORY ANALYSIS
    • 5.13.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • 5.13.2 REGULATORY FRAMEWORK
      • 5.13.2.1 North America
        • 5.13.2.1.1 US
      • 5.13.2.2 Europe
      • 5.13.2.3 Asia Pacific
        • 5.13.2.3.1 China
        • 5.13.2.3.2 Japan
        • 5.13.2.3.3 India
  • 5.14 PATENT ANALYSIS
    • 5.14.1 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS
    • 5.14.2 LIST OF MAJOR PATENTS, 2020-2024
  • 5.15 CASE STUDY ANALYSIS
    • 5.15.1 AMBRA HEALTH UTILIZED AWS CLOUD SERVICES TO PROPEL MEDICAL IMAGING PLATFORM GROWTH
    • 5.15.2 NHS TRUST ADOPTED INSTANT DATA ACCESS VNA TO ESTABLISH UNIFIED PLATFORM FOR DICOM IMAGE DATA STORAGE AND MANAGEMENT
  • 5.16 UNMET NEEDS & END-USER EXPECTATIONS
    • 5.16.1 UNMET NEEDS
    • 5.16.2 END-USER EXPECTATIONS
  • 5.17 BUSINESS MODELS
    • 5.17.1 ENTERPRISE LICENSING MODELS
    • 5.17.2 SOFTWARE-AS-A-SERVICE (SAAS) MODELS
    • 5.17.3 PAY-PER-USE MODELS
    • 5.17.4 HYBRID MODELS
  • 5.18 IMPACT OF 2025 US TARIFF ON VNA & PACS MARKET
    • 5.18.1 INTRODUCTION
    • 5.18.2 KEY TARIFF RATES
    • 5.18.3 PRICE IMPACT ANALYSIS
    • 5.18.4 IMPACT ON COUNTRY/REGION
      • 5.18.4.1 North America
        • 5.18.4.1.1 US
      • 5.18.4.2 Europe
      • 5.18.4.3 Asia Pacific
    • 5.18.5 IMPACT ON END-USE INDUSTRIES
      • 5.18.5.1 Hospitals & clinics
      • 5.18.5.2 Diagnostics centers
      • 5.18.5.3 Ambulatory surgery centers
      • 5.18.5.4 Other end users
    • 5.18.6 CONCLUSION

6 VNA & PACS MARKET, BY MODALITY

  • 6.1 INTRODUCTION
  • 6.2 CT
    • 6.2.1 GROWING NEED FOR IMAGING MODALITIES IN MEDICAL FIELDS TO SUPPORT MARKET GROWTH
  • 6.3 MAMMOGRAPHY
    • 6.3.1 RISING INCIDENCE OF BREAST CANCER TO PROPEL MARKET GROWTH
  • 6.4 ULTRASOUND
    • 6.4.1 TECHNOLOGICAL ADVANCEMENTS IN ULTRASOUND DEVICES TO AID MARKET GROWTH
  • 6.5 MRI
    • 6.5.1 COST-EFFECTIVENESS AND EASY AVAILABILITY IN SMALL HEALTHCARE FACILITIES TO FUEL MARKET ADOPTION
  • 6.6 X-RAY
    • 6.6.1 DEVELOPMENTS IN X-RAY IMAGING TO BOOST ADOPTION OF VNA AND PACS SOLUTIONS
  • 6.7 PET
    • 6.7.1 NEED FOR BETTER MANAGEMENT AND STORAGE OF LARGE DATA VOLUMES TO FAVOR MARKET GROWTH

7 VNA & PACS MARKET, BY DEPLOYMENT MODEL

  • 7.1 INTRODUCTION
  • 7.2 ON-PREMISES DEPLOYMENT MODELS
    • 7.2.1 BETTER CONTROL AND SECURITY FOR SENSITIVE PATIENT DATA TO AUGMENT MARKET GROWTH
  • 7.3 CLOUD-BASED DEPLOYMENT MODELS
    • 7.3.1 TECHNOLOGICAL ADVANCEMENTS IN DIAGNOSTIC IMAGING MODALITIES TO DRIVE MARKET
  • 7.4 HYBRID DEPLOYMENT MODELS
    • 7.4.1 GREATER FLEXIBILITY, SCALABILITY, AND CONTROL OVER DATA MANAGEMENT STRATEGIES TO PROPEL MARKET GROWTH

8 VNA & PACS MARKET, BY PRODUCT TYPE

  • 8.1 INTRODUCTION
  • 8.2 VNA
    • 8.2.1 DEPARTMENT VNA
      • 8.2.1.1 Limitations in addressing scalability and interoperability across diverse departments to hinder market growth
    • 8.2.2 MULTI-DEPARTMENT VNA
      • 8.2.2.1 Multi-department VNA to streamline data management processes and reduce redundancies
    • 8.2.3 MULTI-SITE VNA
      • 8.2.3.1 Multi-site VNA to provide centralized repository for managing medical data and standardizing medical records
  • 8.3 PACS
    • 8.3.1 DEPARTMENT PACS
      • 8.3.1.1 Need for better medical imaging data storage to aid market growth
    • 8.3.2 MULTI-DEPARTMENT PACS
      • 8.3.2.1 Technological advancements in multi-department PACS to improve image retrieval speed and ensure data integrity
    • 8.3.3 MULTI-SITE PACS
      • 8.3.3.1 Advancements in cloud-based PACS solutions to propel market growth

9 VNA & PACS MARKET, BY VENDOR TYPE

  • 9.1 INTRODUCTION
  • 9.2 INDEPENDENT VENDORS
    • 9.2.1 INCREASED FLEXIBILITY, BETTER INTEROPERABILITY, AND IMPROVED SOLUTIONS TO DRIVE MARKET
  • 9.3 THIRD-PARTY VENDORS
    • 9.3.1 NEED FOR INNOVATIVE SOLUTIONS TO DRIVE THIRD-PARTY VENDOR PRESENCE

10 VNA & PACS MARKET, BY APPLICATION

  • 10.1 INTRODUCTION
  • 10.2 CARDIOLOGY
    • 10.2.1 RISING CASES OF CARDIOVASCULAR DISEASES TO DRIVE MARKET
  • 10.3 ORTHOPEDIC
    • 10.3.1 GROWING VOLUME AND COMPLEXITY OF ORTHOPEDIC MEDICAL IMAGING SCANS TO PROPEL MARKET GROWTH
  • 10.4 ONCOLOGY
    • 10.4.1 RISING NUMBER OF CANCER CASES TO DRIVE USE OF VNA AND PACS SOLUTIONS FOR ONCOLOGY
  • 10.5 NEUROLOGY
    • 10.5.1 INCREASING DEMAND FOR ADVANCED NEUROLOGICAL IMAGING TECHNOLOGIES TO SPUR GROWTH
  • 10.6 OBSTETRICS & GYNECOLOGY
    • 10.6.1 USE OF 3D AND 4D IMAGING FOR MONITORING FETUS GROWTH AND DIAGNOSING HIGH-RISK PREGNANCIES TO DRIVE MARKET
  • 10.7 OTHER APPLICATIONS

11 VNA & PACS MARKET, BY END USER

  • 11.1 INTRODUCTION
  • 11.2 HOSPITALS & CLINICS
    • 11.2.1 NEED TO IMPROVE PROFITABILITY OF HEALTHCARE SERVICES TO DRIVE USE OF HCIT IN HOSPITALS
  • 11.3 DIAGNOSTIC CENTERS
    • 11.3.1 LACK OF ADVANCED IMAGING MODALITIES IN SMALL AND MID-SCALE HOSPITALS TO AUGMENT MARKET GROWTH
  • 11.4 AMBULATORY SURGERY CENTERS
    • 11.4.1 INCREASING NUMBER OF INTERVENTIONAL IMAGING PROCEDURES TO SUPPORT MARKET GROWTH
  • 11.5 OTHER END USERS

12 VNA & PACS MARKET, BY REGION

  • 12.1 INTRODUCTION
  • 12.2 NORTH AMERICA
    • 12.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
    • 12.2.2 US
      • 12.2.2.1 US to dominate global VNA & PACS market during study period
    • 12.2.3 CANADA
      • 12.2.3.1 Rising cases of end-stage kidney diseases to propel market growth
  • 12.3 EUROPE
    • 12.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
    • 12.3.2 GERMANY
      • 12.3.2.1 Increasing number of MRI units and diagnostic imaging centers to drive market
    • 12.3.3 UK
      • 12.3.3.1 Rising funding and investments in diagnostic imaging to support market growth
    • 12.3.4 FRANCE
      • 12.3.4.1 Rising target patient population and increasing government-funded investments to fuel uptake of VNA and PACS solutions
    • 12.3.5 ITALY
      • 12.3.5.1 Established healthcare infrastructure to aid market growth
    • 12.3.6 SPAIN
      • 12.3.6.1 Growing access to advanced cancer diagnostics to propel market
    • 12.3.7 REST OF EUROPE
  • 12.4 ASIA PACIFIC
    • 12.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
    • 12.4.2 JAPAN
      • 12.4.2.1 Presence of universal healthcare coverage to fuel market
    • 12.4.3 CHINA
      • 12.4.3.1 Strong government support for healthcare reforms and increased number of medical imaging procedures to drive market
    • 12.4.4 INDIA
      • 12.4.4.1 Improving healthcare infrastructure and increasing private-public partnerships to support market growth
    • 12.4.5 REST OF ASIA PACIFIC
  • 12.5 LATIN AMERICA
    • 12.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
    • 12.5.2 BRAZIL
      • 12.5.2.1 Presence of free and universal healthcare system to propel market growth
    • 12.5.3 MEXICO
      • 12.5.3.1 Rapid technological advancements in imaging solutions to support market growth
    • 12.5.4 REST OF LATIN AMERICA
  • 12.6 MIDDLE EAST & AFRICA
    • 12.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
    • 12.6.2 GCC COUNTRIES
      • 12.6.2.1 Technological integration to spur inclusivity, accessibility, affordability, and growth in healthcare sector
    • 12.6.3 REST OF MIDDLE EAST & AFRICA

13 COMPETITIVE LANDSCAPE

  • 13.1 INTRODUCTION
  • 13.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
    • 13.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN VNA & PACS MARKET
  • 13.3 REVENUE ANALYSIS, 2020-2024
  • 13.4 MARKET SHARE ANALYSIS, 2024
  • 13.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
    • 13.5.1 STARS
    • 13.5.2 EMERGING LEADERS
    • 13.5.3 PERVASIVE PLAYERS
    • 13.5.4 PARTICIPANTS
    • 13.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
      • 13.5.5.1 Company footprint
      • 13.5.5.2 Region footprint
      • 13.5.5.3 Product type footprint
      • 13.5.5.4 Deployment model footprint
      • 13.5.5.5 End-user footprint
  • 13.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
    • 13.6.1 PROGRESSIVE COMPANIES
    • 13.6.2 RESPONSIVE COMPANIES
    • 13.6.3 DYNAMIC COMPANIES
    • 13.6.4 STARTING BLOCKS
    • 13.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
      • 13.6.5.1 Detailed list of key startups/SME players
      • 13.6.5.2 Competitive benchmarking of startups/SME players
  • 13.7 COMPANY VALUATION & FINANCIAL METRICS
    • 13.7.1 FINANCIAL METRICS
    • 13.7.2 COMPANY VALUATION
  • 13.8 BRAND/SOFTWARE COMPARISON
  • 13.9 COMPETITIVE SCENARIO
    • 13.9.1 PRODUCT LAUNCHES
    • 13.9.2 DEALS
    • 13.9.3 OTHER DEVELOPMENTS

14 COMPANY PROFILES

  • 14.1 KEY COMPANIES
    • 14.1.1 AGFA-GEVAERT GROUP
      • 14.1.1.1 Business overview
      • 14.1.1.2 Solutions offered
      • 14.1.1.3 Recent developments
        • 14.1.1.3.1 Deals
      • 14.1.1.4 MnM view
        • 14.1.1.4.1 Right to win
        • 14.1.1.4.2 Strategic choices
        • 14.1.1.4.3 Weaknesses & competitive threats
    • 14.1.2 FUJIFILM HOLDINGS CORPORATION
      • 14.1.2.1 Business overview
      • 14.1.2.2 Solutions offered
      • 14.1.2.3 Recent developments
        • 14.1.2.3.1 Deals
        • 14.1.2.3.2 Other developments
      • 14.1.2.4 MnM view
        • 14.1.2.4.1 Right to win
        • 14.1.2.4.2 Strategic choices
        • 14.1.2.4.3 Weaknesses & competitive threats
    • 14.1.3 SECTRA AB
      • 14.1.3.1 Business overview
      • 14.1.3.2 Solutions offered
      • 14.1.3.3 MnM view
        • 14.1.3.3.1 Right to win
        • 14.1.3.3.2 Strategic choices
        • 14.1.3.3.3 Weaknesses & competitive threats
    • 14.1.4 GE HEALTHCARE
      • 14.1.4.1 Business overview
      • 14.1.4.2 Solutions offered
      • 14.1.4.3 Recent developments
        • 14.1.4.3.1 Product launches
        • 14.1.4.3.2 Deals
      • 14.1.4.4 MnM view
        • 14.1.4.4.1 Right to win
        • 14.1.4.4.2 Strategic choices
        • 14.1.4.4.3 Weaknesses & competitive threats
    • 14.1.5 MERATIVE
      • 14.1.5.1 Business overview
      • 14.1.5.2 Solutions offered
      • 14.1.5.3 Recent developments
        • 14.1.5.3.1 Deals
      • 14.1.5.4 MnM view
        • 14.1.5.4.1 Right to win
        • 14.1.5.4.2 Strategic choices
        • 14.1.5.4.3 Weaknesses & competitive threats
    • 14.1.6 KONINKLIJKE PHILIPS N.V.
      • 14.1.6.1 Business overview
      • 14.1.6.2 Solutions offered
      • 14.1.6.3 Recent developments
        • 14.1.6.3.1 Product launches
        • 14.1.6.3.2 Deals
    • 14.1.7 CANON MEDICAL SYSTEMS CORPORATION
      • 14.1.7.1 Business overview
      • 14.1.7.2 Solutions offered
      • 14.1.7.3 Recent developments
        • 14.1.7.3.1 Deals
        • 14.1.7.3.2 Expansions
    • 14.1.8 INTELERAD. INTELERAD.
      • 14.1.8.1 Business overview
      • 14.1.8.2 Solutions offered
      • 14.1.8.3 Recent developments
        • 14.1.8.3.1 Deals
        • 14.1.8.3.2 Other developments
    • 14.1.9 PAXERAHEALTH
      • 14.1.9.1 Business overview
      • 14.1.9.2 Solutions offered
    • 14.1.10 NOVARAD CORPORATION
      • 14.1.10.1 Business overview
      • 14.1.10.2 Solutions offered
    • 14.1.11 HYLAND SOFTWARE, INC.
      • 14.1.11.1 Business overview
      • 14.1.11.2 Solutions offered
      • 14.1.11.3 Recent developments
        • 14.1.11.3.1 Deals
    • 14.1.12 SIEMENS HEALTHINEERS AG
      • 14.1.12.1 Business overview
      • 14.1.12.2 Solutions offered
      • 14.1.12.3 Recent developments
        • 14.1.12.3.1 Deals
    • 14.1.13 BRIDGEHEAD SOFTWARE LTD.
      • 14.1.13.1 Business overview
      • 14.1.13.2 Solutions offered
      • 14.1.13.3 Recent developments
        • 14.1.13.3.1 Deals
    • 14.1.14 CANOPY PARTNERS
      • 14.1.14.1 Business overview
      • 14.1.14.2 Solutions offered
    • 14.1.15 CRELIOHEALTH INC.
      • 14.1.15.1 Business overview
      • 14.1.15.2 Solutions offered
    • 14.1.16 ASPYRA, LLC
      • 14.1.16.1 Business overview
      • 14.1.16.2 Solutions offered
    • 14.1.17 POSTDICOM
      • 14.1.17.1 Business overview
      • 14.1.17.2 Solutions offered
    • 14.1.18 MEDICASOFT
      • 14.1.18.1 Business overview
      • 14.1.18.2 Solutions offered
    • 14.1.19 ESAOTE S.P.A.
      • 14.1.19.1 Business overview
      • 14.1.19.2 Solutions offered
      • 14.1.19.3 Recent developments
        • 14.1.19.3.1 Product launches
    • 14.1.20 VISUS HEALTH IT GMBH
      • 14.1.20.1 Business overview
      • 14.1.20.2 Solutions offered
  • 14.2 OTHER PLAYERS
    • 14.2.1 ADVAHEALTH SOLUTIONS
    • 14.2.2 SOFTTEAM SOLUTIONS PVT. LTD.
    • 14.2.3 ARO SYSTEMS
    • 14.2.4 CENTRAL DATA NETWORKS
    • 14.2.5 ONEPACS
    • 14.2.6 DEDALUS S.P.A.

15 APPENDIX

  • 15.1 DISCUSSION GUIDE
  • 15.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 15.3 CUSTOMIZATION OPTIONS
  • 15.4 RELATED REPORTS
  • 15.5 AUTHOR DETAILS
»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦